Human flavin-containing monooxygenase (form 3): Polymorphisms and variations in chemical metabolism

Pharmacogenomics

Volumn 3, Issue 3, 2002, Pages 325-339

  Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

Author keywords

Cimetidine; Flavin containing

Indexed keywords

ALIPHATIC AMINE; AMPHETAMINE; AROMATIC COMPOUND; BENZYDAMINE; BIOGENIC AMINE; CHLORPROMAZINE; CYTOCHROME P450; DIMETHYLANILINE MONOOXYGENASE; FOLIC ACID; IMIPRAMINE; METHAMPHETAMINE; MUSCARINIC AGENT; NEUROLEPTIC AGENT; NITROGEN; OLANZAPINE; OXYGEN; PHENETHYLAMINE; PHENOTHIAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; RIBOFLAVIN; TAMOXIFEN; THIAMAZOLE; TRIMETHYLAMINE; TYRAMINE; UNINDEXED DRUG; XANOMELINE; XENOBIOTIC AGENT;

ALLELE; ANIMAL TISSUE; ATOMIC PARTICLE; CATALYSIS; CONTROLLED STUDY; DIET THERAPY; DRUG ACTIVATION; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ENZYME SPECIFICITY; ETHNOLOGY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE INDUCTION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; INBORN ERROR OF METABOLISM; LIVER METABOLISM; MALE; MAMMAL; METABOLIC DISORDER; NONHUMAN; NUCLEOTIDE SEQUENCE; OXYGENATION; POPULATION RESEARCH; REVIEW; SPECIES DIFFERENCE; STRUCTURE ANALYSIS; SWINE; TISSUE SPECIFICITY; TREATMENT PLANNING;

CONTINENTAL POPULATION GROUPS; GENE FREQUENCY; HUMANS; OXYGENASES; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; POLYMORPHISM, GENETIC;

ANIMALIA; MAMMALIA; SUS SCROFA;

EID: 0036265797     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.3.325     Document Type: Review

References (68)

1. Flavin monooxygenases
2. Recent studies on the structure and function of multisubstrate flavin-containing monooxygenase
3. Human flavin-containing monooxygenase: Substrate specificity and role in drug metabolism
4. Oxidative metabolism of tertiary amines by human liver tissue
5. Molecular cloning of the flavin-containing monooxygenase (form II) cDNA from adult human liver
6. Functional characterization of flavin-containing monooxygenase 1B1 expressed in Saccharomyces cereviase and Eschericha coli and analysis of proposed FAD- and membrane binding domains
7. The molecular biology of the flavin-containing monooxygenase of man
8. A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities
9. Structural and catalytic properties of the mammalian flavin-containing monooxygenase
10. Characterization of flavin-containing monooxygenase 5 (FMO5) cloned from human and guinea-pig: Evidence that the unique catalytic properties of FMO5 are not confined to the rabbit ortholog
11. Localization of human flavin-containing monooxygenase genes FMO2 and FMO5 to chromosme 1q
12. Physical mapping of the human connexin 40 (GJA5), flavin-containing monooxygenase and natriuretic peptide receptor a genes on 1q21
13. Human hepatic flavin-containing monooxygenase 1 (FMO3) and 3 (FMO3) developmental expression
14. Immunoquantitation of FMO1 in human liver, kidney and intestine
15. Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1
16. Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: Detection of expressed protein in African-Americans
17. Characterization of expressed full-length and truncated FMO2 from rhesus monkey
18. Identification of active flavin-containing monooxygenase isoform 2 in human lung and characterization of expressed protein
19. Metabolism of nicotine by human liver microsomes: Stereoselective formation of trans-Nicotine N-oxide
20. Chemical, enzymatic and human enantioselective S-oxygenation of cimetidine
21. In vitro-in vivo correlations of human (S)-nicotine metabolism
22. Comparison of human and rhesus monkey in vitro Phase I and Phase II hepatic drug metabolism activities
23. Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes
24. Quantitation and kinetic properties of heptic microsomal and flavin-containing monooxygenase 3 and 5 from humans
25. Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity
26. Tamoxifen metabolism by microsomal cytochrome P450 and flavin-containing monooxygenase 1
27. Estimation of flavin-containing monooxygenase activity in intact hepatocytes of rat, hamster, rabbit, dog and human by using N-oxidation of benzydamine
28. Detoxication of tyramine by the flavin-containing monooxygenase: Stereoselective formation of the trans oxime
29. N-oxygenation of phenethylamine to the trans-oxime by adult human liver flavin-containing monooxygenase and retroreduction of phenethylamine hydroxylamine by human liver microsomes
30. N-Oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): Role in bioactivation and detoxication
31. Flavin-containing monooxygenase-mediated N-oxidation of the M (1)-muscarinic agonist xanomeline
32. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine
33. Stereoselective metabolism of (S)-(-)-nicotine in humans: Formation of trans (S)-(-)-nicotine N-1′-oxide
34. Flavin-monooxygenase 3 (FMO3) polymorphism in a white population: All mutation linkage, functional effects on clozapine and caffeine metabolism
35. Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N- oxidation are positively correlated with genotypes of linked FMO3 gene mutations in a Korean population
36. Isoform specificity of trimethylamine-N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: Selective catalysis by FMO3
37. Human flavin-containing monooxygenase form 3: cDNA expression of the enzymes containing amino acid substitutions observed in individuals with trimethylaminuria
38. Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication
39. Population-specific polymorphisms of the human FMO3 gene: Significance for detoxication
40. The fish odor syndrome: Biochemical, familial and clinical aspects
41. A genetic polymorphism of the N-oxidation of trimethylamine in humans
42. The N-oxidation of trimethylamine in a Jordanian population
43. Studies on the discontinuous N-oxidation of trimethylamine among Jordanian, Ecuadorian and New Guinean populations
44. A pharmacogenetic study of trimethylaminuria in Orientals
45. Missense mutation in flavin-containing monooxygenase 3 gene, FMO3, underlies fish-odour syndrome
46. Biochemical and molecular studies of mild flavin-monooxygenase 3 deficiency
47. Trimethylaminuria ('fish-odour syndrome'): A study of an affected family
48. Trimethylaminuria is caused by mutations of the FMO3 gene in a North American population
49. Mild trimethylaminuria caused by common variants in FMO3 gene
50. Transient trimethylaminuria in childhood
51. Congenital intrahepatic portocaval shunt associated with trimethylaminuria
52. Fishy odour syndrome after acute hepatitis B
53. Exacerbation of symptoms of fish-odour syndrome during menstruation
54. Fracture of the femur, fish odour and copper deficiency in a preterm infant
55. Are brassica vegetables aggravating factors in trimethylaminura (fish odor syndrome)?
56. In vitro and in vivo inhibition of human flavin-containing monooxygenase form 3 in the presence of dietary indoles
57. Trimethylamine, fish odor syndrome: A new method of detection and response to treatment with metronidazole
58. Role of human cytochrome P450 IIE1 in the oxidation of several low molecular weight cancer suspects
59. Psychosocial problems as the major complication of an adolescent with trimethylaminuria
60. Trimethylaminuria associated with seizures and behavioural disturbance: A case report
61. Modulation of human flavin-containing monooxygenase 3 activity by tricyclic antidepressants and other agents: Importance of residue 428
62. Population distribution of human flavin-containing monooxygenase, form 3: Gene polymorphisms
63. The new genomics: Global views of biology
64. MALDI on a chip: Analysis of arrays of low-femtomole to subfemtomole quantities of synthetic oligonucleotides and DNA diagnostic products dispensed by a piezoelectric pipette
65. Nonodor and oral aspects of oral malodor
66. Drug discovery and drug metabolism
67. Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FMO3) gene in patients with fish-odor syndrome
68. Two novel mutations of the FMO3 gene in a proband with trimethylaminuria